Development
DexCom, Inc.
DXCM
$82.26
$1.642.03%
NASDAQ
| 12/31/2023 | 09/30/2023 | 06/30/2023 | 03/31/2023 | 12/31/2022 | |
|---|---|---|---|---|---|
| Revenue | 3.62B | 3.40B | 3.20B | 3.02B | 2.91B |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 3.62B | 3.40B | 3.20B | 3.02B | 2.91B |
| Cost of Revenue | 1.33B | 1.23B | 1.15B | 1.07B | 1.03B |
| Gross Profit | 2.29B | 2.17B | 2.04B | 1.95B | 1.88B |
| SG&A Expenses | 1.19B | 1.18B | 1.13B | 1.08B | 1.01B |
| Depreciation & Amortization | 0.00 | -500.00K | -400.00K | -200.00K | 0.00 |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 3.02B | 2.90B | 2.75B | 2.63B | 2.52B |
| Operating Income | 597.70M | 506.20M | 448.20M | 397.10M | 391.20M |
| Income Before Tax | 710.40M | 597.40M | 503.20M | 419.20M | 390.80M |
| Income Tax Expenses | 168.90M | 220.40M | 145.70M | 126.70M | 49.60M |
| Earnings from Continuing Operations | 541.50 | 377.00 | 357.50 | 292.50 | 341.20 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 541.50M | 377.00M | 357.50M | 292.50M | 341.20M |
| EBIT | 597.70M | 506.20M | 448.20M | 397.10M | 391.20M |
| EBITDA | 783.70M | 676.00M | 609.00M | 557.80M | 547.10M |
| EPS Basic | 1.40 | 0.98 | 0.92 | 0.75 | 0.88 |
| Normalized Basic EPS | 1.15 | 0.97 | 0.81 | 0.67 | 0.63 |
| EPS Diluted | 1.31 | 0.91 | 0.86 | 0.71 | 0.82 |
| Normalized Diluted EPS | 1.05 | 0.87 | 0.74 | 0.62 | 0.57 |
| Average Basic Shares Outstanding | 1.54B | 1.55B | 1.55B | 1.56B | 1.56B |
| Average Diluted Shares Outstanding | 1.69B | 1.70B | 1.70B | 1.69B | 1.70B |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |